Pipeline

Our Pipeline

At Novavax, we leverage our science, our technology and our people to innovate and collaborate in the fight against some of the world’s most significant health challenges.

Download PDF Summary

All of our assets are built using our protein-based nanoparticles and proprietary Matrix-M® adjuvant technology platform.

Starting with our core expertise in infectious disease, we are also investigating other therapeutic areas where we believe our technology could augment and improve upon current therapies.

Scientific rationale, the ability to reach rapid proof-of-concept, unmet medical need and attractiveness to potential partners are what drive our pipeline prioritization.

PPre-clinical
1Phase 1
2Phase 2
3Phase 3
AAuthorized Use
Therapeutic Area
Candidate
Phase: Authorized Use
Partner
Therapeutic Area
Respiratory diseases
COVID-19
Candidate
Nuvaxovid™ (COVID-19 Vaccine, Adjuvanted)*
Phase: Authorized Use
P
1
2
3
A
Partner
Therapeutic Area
Candidate
Phase: 3
Partner
Therapeutic Area
Respiratory diseases
COVID-19 + seasonal influenza
Candidate
COVID-influenza combination (CIC) vaccine
Phase: 3
P
1
2
3
A
Partner
Not yet partnered
Therapeutic Area
Candidate
Phase: 3
Partner
Therapeutic Area
Respiratory diseases
Seasonal influenza
Candidate
Influenza vaccine (older adults)
Phase: 3
P
1
2
3
A
Partner
Not yet partnered
Therapeutic Area
Candidate
Phase: Pre-clinical
Partner
Therapeutic Area
Respiratory diseases
Respiratory syncytial virus (RSV)
Candidate
RSV combinations [RSV, hMPV (Human metapneumovirus), other respiratory]
Phase: Pre-clinical
P
1
2
3
A
Partner
Not yet partnered
Therapeutic Area
Candidate
Phase: Pre-clinical
Partner
Therapeutic Area
Respiratory diseases
H5N1 avian pandemic influenza
Candidate
Highly pathogenic H5N1 avian pandemic influenza vaccine
Phase: Pre-clinical
P
1
2
3
A
Partner
Not yet partnered
Therapeutic Area
Candidate
Phase: Pre-clinical
Partner
Therapeutic Area
Viral infection
Varicella-zoster virus (shingles)
Candidate
Shingles vaccine
Phase: Pre-clinical
P
1
2
3
A
Partner
Not yet partnered
Therapeutic Area
Candidate
Phase: Pre-clinical
Partner
Therapeutic Area
Bacterial disease
Clostridiodes difficile (C. diff) colitis
Candidate
Clostridioides difficile (C. diff)
Phase: Pre-clinical
P
1
2
3
A
Partner
Not yet partnered
Our partners and collaborators leverage our technology platform to advance their own best-in-class medicines addressing significant global health needs.
Therapeutic Area
Candidate
Phase: Authorized Use
Partner
Therapeutic Area
Parasitic diseases
Malaria
Candidate
R21/Matrix-M® adjuvant**
Phase: Authorized Use
P
1
2
3
A
Partner
Therapeutic Area
Candidate
Phase: 1/2
Partner
Therapeutic Area
Respiratory diseases
COVID-19 + seasonal influenza
Candidate
FLUBOK + Nuvaxovid™ (COVID-19 Vaccine, Adjuvanted)***
Phase: 1/2
P
1
2
3
A
Partner
Therapeutic Area
Candidate
Phase: 1/2
Partner
Therapeutic Area
Respiratory diseases
COVID-19 + seasonal influenza
Candidate
FLUZONE High-Dose + Nuvaxovid™ (COVID-19 Vaccine, Adjuvanted)***
Phase: 1/2
P
1
2
3
A
Partner

* Authorized in select geographies under trade names Novavax COVID-19 Vaccine, Adjuvanted; Covovax™; and Nuvaxovid™. Authorization information can be found by country at https://novavaxcovidvaccine.com.

** Commercialized by Serum Institute of India. Granted prequalification by the WHO and distributed by UNICEF to endemic countries in Africa.

*** NCT06695117 Granted Fast Track designation in the U.S.